CVS HEALTH Corp (CVS): Results of Operations and Financial Condition
CVS HEALTH Corp (CVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CVS HEALTH CORPORATION REPORTS STRONG SECOND QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE • Second quarter total revenues increased to $106.1 billion, up 7.3% year-over-year • Second quarter GAAP diluted EPS of $2.31 and Adjusted EPS of $2.58 • Generated y
How this was made
The 30-second read
Why it matters
The key tradable items are the raised GAAP and Adjusted EPS ranges and the increased cash flow from operations guidance, alongside segment drivers (Health Care Benefits margin recovery and Pharmacy economics).
Market read
Guidance raise with explicit EPS and cash flow ranges is likely to drive immediate repricing and set expectations for the rest of 2026.
What to watch
The guidance raise is paired with a cautious outlook for the remainder of the year; traders should watch for any implied assumptions behind the Health Care Benefits and Pharmacy & Consumer Wellness improvements, especially medical cost trends and pharmacy economics.
CVS HEALTH CORPORATION REPORTS STRONG SECOND QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE
Second-quarter revenue, GAAP diluted EPS, Adjusted EPS and adjusted operating income increased year-over-year, with adjusted operating income growth across all operating segments. The Company raised full-year 2026 GAAP diluted EPS, Adjusted EPS and cash flow from operations guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenuesGAAP | $106.1 billion | – | 7.3% |
| Operating incomeGAAP | $4,703 million | – | 97.5% |
| Adjusted operating incomenon-GAAP | $5,157 million | – | 35.4% |
| Net incomeGAAP | $2,995 million | – | – |
| Diluted earnings per shareGAAP | $2.31 | – | – |
| Adjusted EPSnon-GAAP | $2.58 | – | – |
| Six months ended June 30 total revenuesGAAP | $206,522 million | – | – |
| Six months ended June 30 operating incomeGAAP | $9,383 million | – | – |
| Six months ended June 30 adjusted operating incomenon-GAAP | $10,307 million | – | – |
| Six months ended June 30 net incomeGAAP | $5,952 million | – | – |
| Six months ended June 30 diluted earnings per shareGAAP | $4.61 | – | – |
| Six months ended June 30 Adjusted EPSnon-GAAP | $5.16 | – | – |
| Health Care Benefits adjusted operating incomenon-GAAP | $2,426 million | – | 85.5% |
| Health Care Benefits medical benefit ratioother | 87.4% | – | (2.5) % |
| Medical membershipother | 26.0 million | – | – |
| Health Services adjusted operating incomenon-GAAP | $1,733 million | – | 10.0% |
| Pharmacy claims processedother | 473.0 | – | – |
| Pharmacy & Consumer Wellness adjusted operating incomenon-GAAP | $1,475 million | – | 10.2% |
| Prescriptions filledother | 457.0 | – | 4.3% |
| Prior years’ health care costs payable estimates favorable development during the six months ended June 30, 2026other | $1.2 billion | – | – |
| Days claims payable as of June 30, 2026other | 41.7 days | – | – |
| Year-to-date cash flow from operationsGAAP | $10.6 billion | – | – |
| Aetna Claims Assist Manager reduction in processing time for complex claims requiring manual reviewother | over 20% | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Health Care BenefitsPrimarily driven by an increase in the Government business, partially offset by a decline as a result of the Company’s exit of the individual exchange business in 2026. | $37,538 million | – | 3.5% |
| Health ServicesPrimarily driven by pharmacy drug mix and brand inflation, partially offset by continued pharmacy client price improvements. | $51,795 million | – | 11.5% |
| Pharmacy & Consumer WellnessPharmacy drug mix, increased prescription volume, including contributions from the Company’s Rite Aid asset acquisitions, and brand inflation were largely offset by regulatory-related price reductions on certain drugs, the impact of recent generic drug introductions and pharmacy reimbursement pressure. | $33,816 million | – | – |
Year Ending December 31, 2026 outlook
- RevenueAt least $414.0 billion
- NoteGAAP diluted EPS: $6.84-$7.04
- NoteAdjusted EPS: $7.90-$8.10
- NoteCash flow from operations: at least $11.5 billion
What drove it
- Total revenues increased 7.3% driven by revenue growth across all operating segments.
- Operating income increased primarily due to the increase in adjusted operating income and the absence of $833 million in legacy litigation charges recorded in the prior year.
- Health Care Benefits adjusted operating income increased primarily due to improved underlying performance in the Government business and the absence of a $471 million premium deficiency reserve recorded within the Group Medicare Advantage product line in the prior year.
- Health Services adjusted operating income increased primarily due to improved purchasing economics, pharmacy drug mix and modest improvement in the Company’s health care delivery business.
- Pharmacy & Consumer Wellness adjusted operating income increased primarily due to core pharmacy strength and contributions from the Company’s Rite Aid asset acquisitions.
- Prescriptions filled increased primarily due to incremental volume resulting from the Company’s Rite Aid prescription file acquisitions and increased utilization.
Concerns
- The Company maintained a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds.
- Health Services revenue and adjusted operating income drivers were partially offset by continued pharmacy client price improvements.
- Pharmacy & Consumer Wellness revenue drivers were largely offset by regulatory-related price reductions on certain drugs, recent generic drug introductions and pharmacy reimbursement pressure.
- Pharmacy & Consumer Wellness adjusted operating income was partially offset by continued business investments and the impact of consumer dynamics.
- Medical membership of 26.0 million reflected a decline from 26.7 million in the prior year, while remaining consistent compared with March 31, 2026.
What to watch
- Execution of the Health Care Benefits segment margin recovery plan and underlying performance in the Government business.
- Continued elevated cost trends and potential macro headwinds during the remainder of 2026.
- The effect of pharmacy client price improvements, regulatory-related price reductions, generic drug introductions and pharmacy reimbursement pressure.
- Contributions from the Rite Aid asset acquisitions and Rite Aid prescription file acquisitions.
- Progress of CVS Health's GLP-1 support offerings and CVS Caremark formulary expansion.
Balance sheet and cash flow
- Generated year-to-date cash flow from operations of $10.6 billion.
Analysis
CVS Health reported second-quarter total revenues of $106.1 billion, up 7.3% year-over-year, alongside GAAP diluted EPS of $2.31 and Adjusted EPS of $2.58. Operating income was $4,703 million and adjusted operating income was $5,157 million. The operating-income increase reflected higher adjusted operating income across all operating segments and the absence of $833 million in legacy litigation charges recorded in the prior year.
Management, verbatim
Our CVS Health colleagues build trust every day in communities across our country by making healthcare easier for millions of customers, patients and members. As our businesses work together to deliver a technology-powered care engagement experience, we continue to deliver strong performance. We uniquely enable what our customers want the most: simple, connected and convenient access to affordable, quality healthcare, where, when, and how they want it.
David Joyner, CVS Health Chairman and CEO
Not in the filing
stated, not guessed- Gross profit and gross margin
- Free cash flow
- Quarterly cash flow from operations
- Cash and cash equivalents
- Total debt
- Share repurchases
- Dividends
- Capital expenditures
- Full-year operating expense guidance
- Full-year tax-rate guidance
- Previous-release outlook for comparison
- Prior-quarter consolidated financial metrics
- Prior-quarter segment revenue and adjusted operating income metrics
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with CVS’s Q2 2026 operating results and updated full-year 2026 guidance.
Ticker impact
CVS reported Q2 2026 results and raised full-year 2026 guidance, lifting GAAP EPS to $6.84-$7.04 and Adjusted EPS to $7.90-$8.10.
Near-term upside bias as guidance increases, but expect volatility if investors focus on the stated macro and cost-trend risks.
The filing is a primary-source earnings and guidance update with explicit revised ranges and cash flow outlook, which typically drives repricing versus prior expectations.
Market effects
Strength in CVS’s Health Care Benefits and Pharmacy segments, plus GLP-1 support initiatives, may reinforce read-through demand expectations for managed care and retail pharmacy services.
Limited direct regional impact; primarily US healthcare services and payer/pharmacy dynamics.
Low global relevance; US-focused guidance and operations.
Counterpoint
Investors may discount the raise if they believe elevated cost trends and potential macro headwinds will reassert later in 2026, limiting the durability of the margin recovery.
Key entities
- public_companyCVS Health Corporation
Reported Q2 2026 results and raised full-year 2026 GAAP and Adjusted EPS and cash flow guidance.
- executiveDavid Joyner
Chairman and CEO quoted on performance and integrated care engagement.
- business_unitAetna
Launched second generation Aetna Claims Assist Manager (AI claims advisor) to streamline claims processing.
